It’s good news for UK patients as it emerges that the National Institute of Health and Care Excellence has passed positive recommendation for Alnylam’s Onpattro (patisiran) for the treatment of inherited hATTR amyloidosis, a progressive disease related to the production of the abnormal protein transtyretin which can lead to nerve and organ damage and even death.
The decision means that patients in England and Wales will now be able to access the medicine via the NHS. There are around 150 people affected in the UK.
